Editorial: How Will Aducanumab Approval Impact AD Research?
作者信息
Weiner M W, Aisen P S, Beckett L A, Green R C, Jagust W, Morris J C, Okonkwo O, Perrin R J, Petersen R C, Rivera Mindt M, Saykin A J, Shaw L M, Toga A W, Trojanowski J Q
机构信息
Michael W. Weiner, NCIRE, 4150 Clement St, San Francisco, CA 94121, USA. E-mail address:
出版信息
J Prev Alzheimers Dis. 2021;8(4):391-392. doi: 10.14283/jpad.2021.46.
Abstract
摘要
相似文献
1
Editorial: How Will Aducanumab Approval Impact AD Research?社论：阿杜卡努单抗获批将如何影响阿尔茨海默病研究？
J Prev Alzheimers Dis. 2021;8(4):391-392. doi: 10.14283/jpad.2021.46.
2
"Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.阿杜卡奴单抗的“真实世界”准入取决于临床环境和患者的治疗历程。
J Am Geriatr Soc. 2022 Feb;70(2):626-628. doi: 10.1111/jgs.17530. Epub 2021 Nov 9.
3
Aducanumab, amyloid, and culture wars.阿杜卡努单抗、淀粉样蛋白与文化冲突。
BMJ. 2021 Aug 19;374:n2038. doi: 10.1136/bmj.n2038.
4
Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside.用于治疗阿尔茨海默病的阿杜卡努单抗：淀粉样蛋白假说从实验室走向临床。
J Clin Invest. 2021 Oct 15;131(20). doi: 10.1172/JCI154889.
5
Revisiting FDA Approval of Aducanumab.重新审视阿杜卡努单抗的美国食品药品监督管理局批准情况。
N Engl J Med. 2021 Aug 26;385(9):769-771. doi: 10.1056/NEJMp2110468. Epub 2021 Jul 28.
6
US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?美国食品药品监督管理局对阿杜卡努单抗的批准——淀粉样蛋白负荷是阿尔茨海默病临床试验的有效替代终点吗？
JAMA Neurol. 2021 Nov 1;78(11):1307-1308. doi: 10.1001/jamaneurol.2021.3126.
7
What the Aducanumab Approval Reveals About Alzheimer Disease Research.阿杜卡努单抗获批对阿尔茨海默病研究的启示
JAMA Neurol. 2021 Nov 1;78(11):1305-1306. doi: 10.1001/jamaneurol.2021.3404.
8
Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.阿尔茨海默病的争议与进展——阿杜卡单抗获美国食品药品监督管理局批准
N Engl J Med. 2021 Aug 26;385(9):771-774. doi: 10.1056/NEJMp2111320. Epub 2021 Jul 28.
9
Aducanumab: First Approval.阿杜卡奴单抗：首次获批
Drugs. 2021 Aug;81(12):1437-1443. doi: 10.1007/s40265-021-01569-z.
10
Aducanumab for Alzheimer's disease: A regulatory perspective.阿杜卡奴单抗治疗阿尔茨海默病：监管视角。
Pharmacol Res. 2021 Sep;171:105754. doi: 10.1016/j.phrs.2021.105754. Epub 2021 Jul 2.
引用本文的文献
1
Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies.赋能药物研发：利用影像技术的洞见，推动数字健康技术的发展。
Clin Transl Sci. 2023 Mar;16(3):383-397. doi: 10.1111/cts.13461. Epub 2022 Dec 2.
2
What does aducanumab treatment of Alzheimer's disease mean for research on vascular cognitive disorders?阿杜卡努单抗治疗阿尔茨海默病对血管性认知障碍的研究意味着什么？
Cereb Circ Cogn Behav. 2022 Feb 11;3:100044. doi: 10.1016/j.cccb.2022.100044. eCollection 2022.
3
Alzheimer's disease drug development pipeline: 2022.2022年阿尔茨海默病药物研发进展
Alzheimers Dement (N Y). 2022 May 4;8(1):e12295. doi: 10.1002/trc2.12295. eCollection 2022.
本文引用的文献
1
Aducanumab: Appropriate Use Recommendations.阿杜卡奴单抗：合理使用建议。
J Prev Alzheimers Dis. 2021;8(4):398-410. doi: 10.14283/jpad.2021.41.
Zotero 插件